Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Oramed Pharmaceuticals (ORMP) Income towards Parent Company (2022 - 2025)

Oramed Pharmaceuticals (ORMP) has disclosed Income towards Parent Company for 3 consecutive years, with -$4.0 million as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Income towards Parent Company fell 130.17% year-over-year to -$4.0 million, compared with a TTM value of -$12.9 million through Dec 2024, down 1374.93%, and an annual FY2024 reading of -$16.8 million, down 430.52% over the prior year.
  • Income towards Parent Company was -$4.0 million for Q4 2024 at Oramed Pharmaceuticals, up from -$19.6 million in the prior quarter.
  • Across five years, Income towards Parent Company topped out at $13.3 million in Q4 2023 and bottomed at -$19.6 million in Q3 2024.
  • Average Income towards Parent Company over 3 years is -$4.5 million, with a median of -$4.6 million recorded in 2023.
  • Peak annual rise in Income towards Parent Company hit 342.79% in 2024, while the deepest fall reached 498.11% in 2024.
  • Year by year, Income towards Parent Company stood at -$12.3 million in 2022, then skyrocketed by 207.87% to $13.3 million in 2023, then tumbled by 130.17% to -$4.0 million in 2024.
  • Business Quant data shows Income towards Parent Company for ORMP at -$4.0 million in Q4 2024, -$19.6 million in Q3 2024, and $9.2 million in Q2 2024.